9 years of historical data (2016–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bicycle Therapeutics plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $111M | $815M | $644M | $878M | $1.5B | $344M | $104M | — | — | — |
| Enterprise Value | $-758647581 | $-55120698 | $162M | $583M | $1.1B | $223M | $14M | — | — | — |
| P/E Ratio → | -1.98 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.16 | 23.10 | 23.85 | 60.70 | 130.42 | 33.08 | 7.55 | — | — | — |
| P/B Ratio | 0.42 | 1.03 | 1.73 | 3.24 | 4.41 | 3.60 | 1.12 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -1.56 | 6.01 | 40.32 | 96.71 | 21.51 | 1.01 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Bicycle Therapeutics plc earns an operating margin of -595.0%. Operating margins have expanded from -806.6% to -595.0% over the past 3 years, signaling improving operational efficiency. A negative ROE of -29.0% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -390.3% | -390.3% | -480.1% | 100.0% | 100.0% | -219.0% | -85.1% | -190.9% | -476.0% | — |
| Operating Margin | -595.0% | -595.0% | -704.1% | -806.6% | -561.0% | -500.1% | -190.6% | -304.7% | -787.0% | — |
| Net Profit Margin | -479.2% | -479.2% | -669.7% | -779.3% | -571.2% | -491.0% | -221.8% | -306.1% | -789.3% | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -29.0% | -29.0% | -56.3% | -36.5% | -30.3% | -54.1% | -261.9% | — | — | -168.4% |
| ROA | -21.8% | -21.8% | -35.9% | -25.3% | -20.9% | -37.6% | -31.9% | -28.1% | -37.9% | -114.2% |
| ROIC | — | — | — | — | — | — | -663.7% | — | — | — |
| ROCE | -29.7% | -29.7% | -43.0% | -29.1% | -22.6% | -43.4% | -30.2% | -31.7% | -44.7% | -168.2% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $880M exceeds total debt of $9M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.12 | 0.16 | 0.13 | 0.17 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.10 | -1.30 | -1.09 | -1.14 | -1.26 | -0.97 | — | — | -1.17 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -121.31 | -121.31 | -58.21 | -34.88 | -21.99 | -113.70 | — | — | — | — |
Net cash position: cash ($880M) exceeds total debt ($9M)
Short-term solvency ratios and asset-utilisation metrics
Bicycle Therapeutics plc's current ratio of 13.81x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 6.92x to 13.81x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.81 | 13.81 | 8.08 | 6.92 | 12.65 | 6.73 | 11.81 | 8.60 | 7.57 | 2.96 |
| Quick Ratio | 13.81 | 13.81 | 8.08 | 6.92 | 12.65 | 6.73 | 11.81 | 8.60 | 7.57 | 2.96 |
| Cash Ratio | 13.08 | 13.08 | 7.57 | 6.36 | 12.11 | 5.88 | 10.44 | 7.10 | 7.16 | 2.47 |
| Asset Turnover | — | 0.04 | 0.05 | 0.04 | 0.02 | 0.06 | 0.13 | 0.09 | 0.03 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 368.91 | 325.26 | 535.20 | 371.65 | 514.06 | 188.97 | 578.65 | 531.73 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bicycle Therapeutics plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $58M | $36M | $30M | $25M | $19M | $11M | $13M | $13M | $18M |
Compare BCYC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| BCYCYou | $111M | -2.0 | — | — | -390.3% | -595.0% | -29.0% | — | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 9 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BCYC stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonBicycle Therapeutics plc's current P/E ratio is -2.0x. This places it at the 50th percentile of its historical range.
Bicycle Therapeutics plc's return on equity (ROE) is -29.0%. The historical average is -90.9%.
Based on historical data, Bicycle Therapeutics plc is trading at a P/E of -2.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Bicycle Therapeutics plc has -390.3% gross margin and -595.0% operating margin.